Last updated: August 27, 2026
Cisplatin is an off-patent platinum chemotherapy with limited opportunity for premium pricing as a conventional injection. The strongest commercial opportunities are in chloride-controlled ready-to-use presentations, supply-chain reliability, toxicity-reduction systems, local delivery, and combination products. Excipient selection is constrained by cisplatin’s hydrolysis, chloride dependence, aluminum incompatibility, nephrotoxicity, and hazardous-drug handling requirements.
What excipients are used in cisplatin injection?
Approved cisplatin injections generally use a simple aqueous formulation containing cisplatin, sodium chloride, water for injection, and, in some products, pH-adjusting hydrochloric acid. Product-specific labels must control the exact formulation because cisplatin stability depends on chloride concentration and storage conditions.[1-3]
| Formulation attribute |
Commercial role |
| Cisplatin concentration |
Commonly 1 mg/mL in single-dose vials |
| Sodium chloride |
Maintains chloride concentration and suppresses excessive aquation |
| Water for injection |
Primary solvent |
| Hydrochloric acid |
May adjust pH in specific products |
| Preservatives |
Generally avoided because the product is a cytotoxic single-dose injection |
| Aluminum-containing components |
Avoided because cisplatin can react with aluminum and form precipitate |
Cisplatin undergoes aquation when chloride concentration falls. The resulting reactive species are pharmacologically active but can also accelerate degradation and create formulation, handling, and compatibility risks. Labels commonly require dilution in chloride-containing solutions, such as 0.9% sodium chloride or dextrose-saline mixtures.[1,2]
Why is sodium chloride important in cisplatin formulation?
Sodium chloride is a functional stability excipient, not simply an isotonicity agent. Chloride ions help maintain cisplatin in its neutral dichloro form and reduce conversion to aquated species during storage and dilution.
A formulation with insufficient chloride may have:
- Faster chemical degradation
- Greater risk of precipitation or discoloration
- More demanding storage controls
- Reduced compatibility with infusion materials
- Higher variability after dilution into an infusion bag
This creates a commercial opportunity for optimized chloride-controlled premixes. The product must balance stability with infusion-volume requirements, sodium load, container compatibility, and hospital hydration protocols.
Which excipients and materials create compatibility risks?
Aluminum is a well-established compatibility concern. Cisplatin labels warn against contact with aluminum-containing needles, syringes, catheters, or administration sets because a black precipitate may form.[1,2] Commercial products should use qualified polymeric or stainless-steel contact materials and provide clear administration instructions.
Other development risks include:
- Sulfate-containing solutions
- Bicarbonate-containing solutions
- Low-chloride diluents
- Uncontrolled pH
- Excessive light or temperature exposure
- Adsorption to infusion components
- Incomplete mixing in high-volume bags
The highest-value excipient work is therefore compatibility engineering rather than adding a large excipient package.
What formulations are protected by cisplatin patents?
The original cisplatin composition and conventional injectable formulation are long off-patent. The commercial opportunity lies in later delivery technologies, including liposomes, polymeric nanoparticles, albumin-based carriers, hydrogels, implants, and tumor-localized systems.
| Formulation type |
Potential benefit |
Principal development barrier |
| Ready-to-use premix |
Reduces pharmacy compounding and handling |
Long-term stability and container compatibility |
| Concentrated solution |
Reduces infusion volume |
Solubility, precipitation, and dosing accuracy |
| Lyophilized cisplatin |
May improve shelf life and logistics |
Reconstitution control and preservation of particle-free solution |
| Liposomal cisplatin |
May alter distribution and toxicity |
Complex CMC, drug loading, release testing |
| Polymeric nanoparticle |
Can support tumor targeting or sustained release |
Scale-up, residual solvents, regulatory characterization |
| Hydrogel or implant |
Enables local treatment |
Surgical delivery, dose uniformity, local tolerability |
| Cisplatin prodrug system |
May reduce systemic exposure |
New active-moiety and pharmacology questions |
Patent protection for these systems is generally directed to the carrier, drug-loading method, release profile, targeting ligand, manufacturing process, or therapeutic use. A delivery patent does not restore exclusivity to unmodified cisplatin. Its value depends on whether the formulation produces clinically meaningful advantages and whether the claims survive validity and enablement challenges.
When does cisplatin lose exclusivity?
Cisplatin lost basic small-molecule exclusivity decades ago. The original product was approved in the United States in 1978, and conventional cisplatin injection is supplied through generic 505(j) abbreviated new drug applications.[4,5]
| Exclusivity category |
Cisplatin position |
| New chemical entity exclusivity |
Expired |
| Basic composition patent |
Expired |
| Conventional injection patent estate |
Generally expired |
| Generic pathway |
ANDA under section 505(j) |
| Biosimilar pathway |
Not applicable |
| Pediatric exclusivity |
No current foundational relevance |
| Orphan exclusivity |
Product- and indication-specific, not a general cisplatin right |
| New formulation exclusivity |
Possible only for a qualifying new product |
| Method-of-use exclusivity |
Possible for a separately protected approved indication |
The practical consequence is that a new entrant cannot rely on cisplatin itself for market exclusivity. A defensible launch requires a differentiated formulation, delivery system, manufacturing process, device, combination, or clinically supported indication.
What is the FDA regulatory status of cisplatin?
Cisplatin is an FDA-approved prescription antineoplastic administered intravenously. It is used across multiple malignancies, including testicular, ovarian, bladder, head and neck, lung, cervical, and other cancers, depending on the product labeling and treatment protocol.[1,2]
The standard commercial pathway for a conventional generic injection is an ANDA. A materially altered formulation, such as a nanoparticle or depot product, may require a 505(b)(2) application or a full 505(b)(1) application, depending on the extent of reliance on the reference product and the amount of new clinical evidence required.
What is the Orange Book status of cisplatin?
The Orange Book remains relevant to specific NDA and ANDA products, but cisplatin does not have a meaningful active foundational patent barrier comparable to a recently launched branded oncology drug.[4] Any current patent analysis must be performed at the product level because listed patents, regulatory exclusivity, and dispensing information can differ among NDA products.
For a conventional cisplatin generic, the central regulatory issues are usually:
- Pharmaceutical equivalence
- Bioequivalence or applicable waiver strategy
- Sterility assurance
- Particulate control
- Container-closure integrity
- Extractables and leachables
- In-use stability after dilution
- Cytotoxic manufacturing controls
- Drug-shortage and supply continuity requirements
How many patents cover cisplatin?
No single number accurately describes the cisplatin patent estate without defining the product, jurisdiction, formulation, and claim type. The foundational cisplatin molecule and conventional injection are off-patent, while later patents may cover delivery platforms or therapeutic combinations.
A useful commercial classification is:
| Patent category |
Current relevance |
| Cisplatin compound claims |
Low; foundational protection expired |
| Simple aqueous injectable composition |
Low unless tied to a novel stability or packaging feature |
| Nanoparticles and liposomes |
Potentially high |
| Local delivery and implants |
Potentially high |
| Combination therapy |
Variable and indication-dependent |
| Manufacturing process |
Potentially relevant if process-specific and difficult to design around |
| Administration device |
Relevant where the device controls exposure or delivery |
| Biomarker-selected use |
Potentially relevant but vulnerable to obviousness and enablement challenges |
Patent strength is highest when claims combine a defined carrier, measurable drug-loading parameters, release characteristics, manufacturing controls, and a clinically supported safety or efficacy advantage. Broad claims covering "cisplatin in a nanoparticle" are more vulnerable to prior-art and written-description challenges.
Are there Paragraph IV challenges involving cisplatin?
A Paragraph IV certification is relevant only when an ANDA applicant seeks approval for a product associated with an unexpired Orange Book-listed patent. Because conventional cisplatin injection has been generic for many years, the commercial importance of Paragraph IV litigation is limited for the basic product.
Paragraph IV risk becomes more relevant in three situations:
- A branded reformulated cisplatin product obtains FDA approval.
- The sponsor lists formulation, use, device, or manufacturing patents in the Orange Book.
- A generic applicant seeks approval for a product whose label overlaps a patented indication or formulation.
Potential litigation would focus on claim construction, obviousness, written description, enablement, patent listing eligibility, and whether the proposed ANDA label induces infringement. A patent covering an innovative cisplatin delivery system would not automatically block an ordinary cisplatin injection.
What generic entry risks exist for cisplatin?
Generic entry risk is high for standard vials and low-complexity solutions because the active ingredient is old, the clinical use is established, and multiple manufacturers can supply the product. The main barriers are operational rather than patent-based.
Manufacturing and IP barriers
A new entrant must manage:
- Potent-compound containment
- Worker exposure controls
- Sterile filling
- Low particulate levels
- Container compatibility
- Stable chloride concentration
- Reliable API supply
- Controlled destruction of cytotoxic waste
- Hospital acceptance and shortage substitution
API manufacturing may require sophisticated containment and impurity controls, but those requirements generally do not create durable exclusivity. A process patent can have value only if the process materially lowers cost, improves impurity control, or enables a differentiated dosage form.
Generic launch scenarios
| Launch scenario |
Commercial outlook |
| Standard 1 mg/mL vial |
Price competition and limited differentiation |
| Ready-to-use infusion bag |
Better pharmacy workflow and potential contracting advantage |
| Smaller-volume concentrated product |
Potential value where fluid restriction matters |
| Premix with validated stability |
Opportunity in hospitals seeking reduced compounding |
| Nanoparticle or liposomal product |
Higher development cost with potential premium pricing |
| Local depot or hydrogel |
High clinical and regulatory risk, but stronger differentiation |
| Combination product |
Possible exclusivity if clinically and legally structured |
How can excipients create commercial opportunities?
The most practical opportunity is a hospital-use formulation that reduces preparation burden while preserving cisplatin stability.
Ready-to-use cisplatin bags
Ready-to-use products can reduce pharmacy manipulation, occupational exposure, compounding errors, and preparation time. Their commercial value increases if they offer:
- Multiple standard dose strengths
- Long refrigerated shelf life
- Documented room-temperature excursion stability
- Low sorption to bag and tubing materials
- Clear labeling for hazardous-drug handling
- Compatibility with automated dispensing systems
A ready-to-use product must compete with the cost of generic vials and the hospital’s existing pharmacy workflow. Its value proposition is strongest where chemotherapy preparation capacity is constrained or hazardous-drug compounding costs are high.
Low-volume and concentrated formulations
A concentrated formulation could reduce fluid burden, which may matter for patients at risk of renal or cardiac complications. The product must preserve stability at the higher concentration and maintain dosing accuracy. The formulation cannot be evaluated only on API solubility; chloride concentration, pH, precipitation risk, and infusion-line compatibility are central.
Excipient systems for nephrotoxicity reduction
Excipient-enabled systemic products may aim to alter distribution or reduce renal tubular exposure. Candidate approaches include lipid carriers, polymeric particles, albumin-binding systems, and controlled-release matrices. These systems face a high evidence threshold because cisplatin’s antitumor activity and toxicity are linked to exposure. A reduction in nephrotoxicity that also reduces tumor exposure would have limited commercial value.
How does cisplatin compare with carboplatin and oxaliplatin?
Cisplatin has greater nephrotoxicity, ototoxicity, emetogenicity, and hydration burden than carboplatin. Carboplatin is often easier to administer but may have greater dose-limiting myelosuppression. Oxaliplatin has a different clinical profile and is strongly associated with peripheral sensory neuropathy.[6]
| Attribute |
Cisplatin |
Carboplatin |
Oxaliplatin |
| Generic status |
Long established |
Long established |
Long established |
| Hydration burden |
High |
Lower |
Lower |
| Renal toxicity |
Major concern |
Lower relative risk |
Lower relative risk |
| Key dose-limiting toxicity |
Renal, auditory, neurologic |
Myelosuppression |
Peripheral neuropathy |
| Formulation opportunity |
Stability and toxicity reduction |
Dosing convenience |
Neuropathy management and combinations |
| Price differentiation |
Weak for standard injection |
Weak for standard injection |
Weak for standard injection |
Cisplatin remains clinically important because some tumors have superior response to cisplatin-containing regimens. That clinical position supports commercial investment in safer delivery rather than in another undifferentiated vial.
What patent litigation and licensing opportunities affect cisplatin?
There is limited strategic value in licensing the cisplatin molecule itself. Licensing opportunities are more likely to involve:
- Liposome or nanoparticle platforms
- Tumor-targeting ligands
- Local delivery matrices
- Renal-sparing technologies
- Premix manufacturing platforms
- Hazardous-drug packaging and administration systems
- Combination regimens with proprietary agents
A licensee should evaluate freedom to operate across composition, manufacturing, use, and device claims. The most relevant competitors may not be generic cisplatin manufacturers. They may be companies developing alternative platinum agents, antibody-drug conjugates, localized chemotherapy, or kidney-sparing delivery systems.
Litigation risk is highest for a reformulated product that seeks a premium price. The sponsor must establish that its formulation has a non-obvious technical effect, measurable clinical benefit, and claims that can be enforced against a practical competing product.
What revenue exposure does cisplatin create?
Standard cisplatin has low revenue potential per dose because generic pricing is competitive and hospitals often purchase through group purchasing organizations. Revenue exposure is concentrated in volume, reliable supply, and institutional contracts.
A differentiated product can capture more value through:
- Reduced pharmacy labor
- Fewer preparation steps
- Lower wastage
- Better shortage resilience
- Reduced exposure risk for healthcare workers
- Lower hospitalization or supportive-care costs
- Improved patient selection
- Reduced nephrotoxicity or hydration requirements
The strongest business case is usually a total-cost-of-care argument rather than a high API price. A reformulated product that requires new administration equipment or extensive clinical validation may not achieve adoption without a clear reduction in renal injury, infusion time, or pharmacy cost.
Key Takeaways
- Cisplatin’s foundational composition and conventional injection are off-patent.
- Sodium chloride is a critical stability excipient because chloride concentration controls cisplatin aquation.
- Aluminum contact materials are a major compatibility risk and should be excluded from the product-contact system.
- Standard cisplatin vials face high generic competition and limited pricing power.
- Ready-to-use premixes, concentrated solutions, and pharmacy-friendly packaging offer the lowest-risk commercial opportunities.
- Nanoparticles, liposomes, hydrogels, and local delivery systems offer stronger differentiation but require substantial CMC and clinical investment.
- Cisplatin is a small molecule, so biosimilar regulation does not apply.
- Paragraph IV risk is limited for conventional cisplatin but may emerge around a newly approved reformulated product.
- Licensing value is concentrated in delivery, toxicity reduction, manufacturing, and administration technologies.
- Patent strength depends on a technically specific formulation and demonstrated clinical benefit, not on cisplatin itself.
FAQs
Can cisplatin be formulated without sodium chloride?
It can be formulated in other systems, but removing chloride creates a significant stability and compatibility challenge. Any chloride-free formulation requires rigorous degradation, precipitation, container, and in-use stability data.
Is a cisplatin liposome automatically patentable?
No. Patentability depends on novelty, non-obviousness, written description, enablement, and claim scope. A liposomal product requires defined structural and performance characteristics that distinguish it from prior art.
Does cisplatin qualify for biosimilar approval?
No. Cisplatin is a chemically synthesized small molecule. Conventional copies use the generic drug pathway rather than the biosimilar pathway.
What is the most attractive near-term cisplatin product opportunity?
A stable, ready-to-use, chloride-controlled infusion presentation is the most practical near-term opportunity. It has lower development risk than a nanoparticle or local-delivery product and can target hospital workflow, safety, and shortage resilience.
Can an improved cisplatin formulation obtain new exclusivity?
Potentially. A qualifying new formulation, delivery system, method of use, or combination may receive patent protection and, in some cases, regulatory exclusivity. The protection would apply to the improvement, not to unmodified cisplatin.
References
-
DailyMed. (2023). Cisplatin injection, solution prescribing information. U.S. National Library of Medicine.
-
Pfizer Inc. (2023). Cisplatin injection prescribing information. U.S. Food and Drug Administration.
-
U.S. Food and Drug Administration. (2023). Inactive ingredient database. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
National Cancer Institute. (2024). Cisplatin, carboplatin, and oxaliplatin drug information. National Institutes of Health.
